CRYSVITA safety and effectiveness in Korean patients
Part of Bones, joints & muscles, Hormones & metabolism clinical trials.
This study looks at the safety and effectiveness of CRYSVITA (burosumab) in real-world use among patients in South Korea. If you are already prescribed CRYSVITA for X-linked hypophosphatemia, your doctor may ask you to join this survey to help track how well it works and any side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are currently being treated with CRYSVITA, exactly as your doctor prescribed it.
- You (or your legal guardian, if you are a child) have signed a written consent form to join this study.
- CRYSVITA is safe for you to take (no medical reasons that would make it dangerous for you).
- You are not using CRYSVITA for any other condition or purpose.
- This is your first time taking CRYSVITA as part of this study (not if you already started it before this study began).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how safe and effective a pill called Sotyktu is for people with moderate-to-severe plaque psoriasis in real-life medical settings in Korea. If you are 19 or older and are about to start Sotyktu for your psoriasis as your doctor prescribes, this study may be an option for you.
This study looks at the safety of the drug fedratinib in Korean patients with myelofibrosis. It will help doctors better understand how well patients tolerate the drug when it's used as approved.
This study is checking the safety of a drug called Luspatercept (brand name Reblozyl) for people in Korea who have myelodysplastic syndrome (a blood disorder) or beta-thalassemia (a type of inherited anemia). It is designed to monitor how safe the drug is when used as prescribed by your doctor.
This study tracks how well Cosentyx works in real-world use for people with hidradenitis suppurativa, plaque psoriasis, or juvenile idiopathic arthritis. It helps doctors understand the medicine's long-term effects in Korean patients.
This study monitors the safety of VYLOY (a cancer medicine) given to people in South Korea with stomach or gastroesophageal junction cancer. It helps doctors learn more about real-world side effects and how well patients do on treatment.
This study looks at real-world safety data for patients in South Korea who are taking Capivasertib as prescribed by their doctor according to the approved label. It helps ensure the drug continues to be safe and effective for people who need it.
Hear when a new FGF23-related Hypophosphataemic Rickets and Osteomalacia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.